A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: AZD2936

Sponsor

AstraZeneca